Highest-materiality recent filing
ChronoScale director Scott Davis resigns after Ekso sale; gets $709,500 and 51,626 RSUs
Scott Davis, Ekso Bionics CEO and ChronoScale board member, resigned from the board effective October 3, 2026, with no disagreements cited; the Ekso sale closed September 30, 2026.
ChronoScale completed the sale of its Ekso Bionics business unit on September 30, 2026.
ChronoScale extends $2M loan maturity to Nov 12, 2026; permits Ekso Bionics sale
Term loan of $2.0M outstanding extended to Nov 12, 2026 from Sept 12, 2026 via amendment with B. Riley Commercial Capital.
ChronoScale extends Microsoft AI partnership to 3 years for 50 MW deployment
Partnership term with Microsoft extended from two to three years for a 50 MW AI compute deployment in North America.
ChronoScale CFO Jerome Wong signs new employment offer with $400K salary, 300K RSUs
Offer letter effective Aug 16, 2026; base salary $400,000/year, target bonus 60% of base.
On July 1, 2026, ChronoScale completed a holding company reorganization, merging with a subsidiary of newly formed ChronoScale Holdings.
ChronoScale files Cloud financials: FY2025 revenue $84.4M, net loss $72.7M
Cloud FY2025 revenue $84.4M (up from $29.0M in FY2024); net loss $72.7M vs $75.3M prior year.
ChronoScale appoints Andrew Schaap to board, grants 200,000 restricted shares
Board expanded from 7 to 8 members; Schaap appointed effective June 29, 2026.
ChronoScale enters $100M unsecured demand note from Applied Digital Corporation
Applied Digital Corporation makes $100M unsecured demand grid promissory note available to ChronoScale.
Chronoscale plans to divest Ekso Bionics, focus on cloud business
Board committed on May 29, 2026 to divest wholly owned subsidiary Ekso Bionics, Inc.
ChronoScale Amends Phantom PSU Awards for Three Executives After Change in Control
Scott Davis's Phantom PSU amended to settle as 109,357 shares of common stock plus $1,000,000 cash.
Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.
Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.
Ekso Bionics to close business combination with Applied Digital, PIPE $15.75M, ticker becomes CHRN
Business combination with Applied Digital subsidiary closes May 5, 2026; company renames to ChronoScale Corporation.
Ekso to merge with Applied Digital Cloud in reverse merger; APLD to own ~97%, rename to ChronoScale
Exchange: Ekso issues 138.2M shares to APLD for 100% of Cloud; APLD expects ~97% ownership of combined company.
Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants
Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.
Ekso Bionics and Applied Digital propose business combination; EKSO holders get ~3% of ChronoScale
Applied Digital to spin out cloud business, combine with EKSO to form ChronoScale Corporation.
Ekso Bionics awards 114.5k RSUs and 257k phantom PSUs to Davis, Wong, Jones; new severance deals
Scott Davis: 80k RSUs + 185k phantom PSUs; severance 9 months (non-CIC) or 18 months salary (CIC).
Ekso Bionics raises $3.2M net in registered direct offering of 769,490 shares at $4.81
Sold 769,490 shares at $4.81 per share to institutional investors; net proceeds ~$3.2M.
Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry
Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.
Ekso Bionics enters $2M secured loan with B. Riley at 10% interest
Agreement with B. Riley Commercial Capital for up to $2.0M secured term loan, maturing Sept 14, 2026 or upon qualified equity raise of $2.4M.
Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M
Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
Ekso Bionics updates reverse stock split effective date to June 2, 2025
Reverse stock split at 1-for-15 effective June 2, 2025; originally planned May 27.
Reverse split ratio set at 1-for-15; effective 12:01 a.m. PT on May 27, 2025.
Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution
Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.
Ekso Bionics raises $4.15M via warrant exercise; issues new 10.5M-share warrant at $0.4239
Existing holder exercises 9.8M warrants for $4.15M at $0.4239/share; company receives cash proceeds.
Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024
Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.
Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary
Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply
Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.
Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement
Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.
Ekso Bionics raises ~$5.1M net in underwritten public offering of units with warrants
Issued 3.1M units at $1.00/unit (share + Series A/B warrants) and 2.9M pre-funded units at $0.9990/unit.
Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share
Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
Ekso Bionics board elects annual say-on-pay vote after stockholder advisory frequency vote
Board determined on July 25, 2024 to hold future advisory votes on executive compensation annually.
Ekso Bionics shareholders approve all proposals at 2024 annual meeting
All five director nominees elected: Scott Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, Deborah Lafer Scher.
Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal
Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.
Ekso Bionics reports record 2023 revenue of $18.3M, up 42% YoY
Full-year 2023 revenue $18.3M (FY22: $12.9M); sold 151 EksoHealth units.
Ekso Bionics raises ~$4.0M in registered direct offering of 2.97M shares at $1.55/share
Sold 2,967,742 common shares at $1.55 each; net proceeds ~$4.0M after fees and expenses.
Ekso Bionics files consent of independent auditor; no material news disclosed
Filed Exhibit 23.1: Consent of WithumSmith+Brown, PC, independent registered public accounting firm.
Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M
Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).
Ekso Bionics regains Nasdaq minimum bid price compliance
Received Nasdaq written notice on Nov 14, 2023, confirming compliance with $1.00 minimum bid price rule.
Ekso Bionics Q3 revenue up 38% to $4.6M; net loss narrows to $0.24/share
Revenue of $4.6M, up 38% YoY; gross margin improved to 53% from 51%.
Ekso Bionics receives $700K from Parker-Hannifin; Nasdaq gives bid price deficiency notice
Received $700,000 from Parker-Hannifin in settlement of warranty obligations under Asset Purchase Agreement.
Ekso Bionics amends loan: extends maturity to 2026, interest at prime or 4.5% min
Term Loan interest set to greater of Pacific Western Bank prime rate or 4.50% annually.
Ekso Bionics files prospectus to sell up to $5.0M shares in at-the-market offering
Filed prospectus supplement under existing ATM agreement with H.C. Wainwright & Co. for up to $5.0M of common stock.
Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share
Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.
Ekso Bionics removes $6.75 floor from ATM offering; shareholders approve share plan increase
Amended at-the-market offering agreement with H.C. Wainwright to remove $6.75 per share floor, effective June 12, 2023.
Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M
Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.
Ekso Bionics director Stern resigns; CEO bonus potential raised to 75% of salary
Stanley Stern resigns from board effective April 26, 2023; no disagreement with Company.
Ekso Bionics reports FY 2022 revenue up 15% to $12.9M, net loss widens to $15.1M
Full-year revenue $12.9M (up 15% YoY); Q4 revenue $3.6M vs $4.1M year ago.
Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022
Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.
Ekso Bionics appoints CEO Scott G. Davis to its Board of Directors
Appointment effective Dec 8, 2022; term expires at 2023 Annual Meeting.
Scott Davis, a member of the Board of Directors of the Company (the “Board”) and Chief Executive Officer (“CEO”) of Ekso, resigned from his position as a member of the Board, effective as of October 3, 2026. There were no disagreements between the Company and Mr. Davis that led to his decision to resign.
On June 29, 2026, Mr. Schaap was appointed to serve on the Board.
On June 29, 2026, the board of directors (the “Board”) of ChronoScale Corporation, a Nevada corporation (the “Company”), increased the size of the Board from seven to eight members and appointed Mr. Andrew Cordell Schaap to serve as a member of the Board to fill the resulting vacancy, effective as of June 29, 2026.
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher
the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg
the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher
the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher
Max materiality 0.95 · Median 0.62 · Most common event other_material